Clinical Trial

A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia Vera

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated May 11, 2025 (before its estimated August 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of 9MW3011 in Chinese patients with Polycythemia Vera（PV）.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-12-23.
Trial Details
NCT Number NCT06752746
Lead Sponsor Mabwell (Shanghai) Bioscience Co., Ltd.
Conditions Polycythemia Vera
Enrollment 108 participants
Start Date 2024-03-21
Primary Completion 2025-08-31 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-05-11